327 related articles for article (PubMed ID: 18698873)
1. Use of botulinum toxin A in adult neurological disorders: efficacy, tolerability and safety.
Schulte-Mattler WJ
CNS Drugs; 2008; 22(9):725-38. PubMed ID: 18698873
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of botulinum toxin in neurological indications.
Ward AB; Molenaers G; Colosimo C; Berardelli A
Eur J Neurol; 2006 Dec; 13 Suppl 4():20-6. PubMed ID: 17112346
[TBL] [Abstract][Full Text] [Related]
3. [Mechanism of therapy effects by botulinum neurotoxin].
Alajbegović A; Alajbegović S; Resić H
Med Arh; 2008; 62(1):53-5. PubMed ID: 18543757
[TBL] [Abstract][Full Text] [Related]
4. An Update on Botulinum Toxin in Neurology.
Chiu SY; Burns MR; Malaty IA
Neurol Clin; 2021 Feb; 39(1):209-229. PubMed ID: 33223084
[TBL] [Abstract][Full Text] [Related]
5. Botulinum Toxin A for Sialorrhoea Associated with Neurological Disorders: Evaluation of the Relationship between Effect of Treatment and the Number of Glands Treated.
Restivo DA; Panebianco M; Casabona A; Lanza S; Marchese-Ragona R; Patti F; Masiero S; Biondi A; Quartarone A
Toxins (Basel); 2018 Jan; 10(2):. PubMed ID: 29382036
[No Abstract] [Full Text] [Related]
6. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
Luvisetto S; Gazerani P; Cianchetti C; Pavone F
Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic uses of botulinum toxin: from facial palsy to autonomic disorders.
de Maio M
Expert Opin Biol Ther; 2008 Jun; 8(6):791-8. PubMed ID: 18476790
[TBL] [Abstract][Full Text] [Related]
8. More than at the neuromuscular synapse: actions of botulinum neurotoxin A in the central nervous system.
Mazzocchio R; Caleo M
Neuroscientist; 2015 Feb; 21(1):44-61. PubMed ID: 24576870
[TBL] [Abstract][Full Text] [Related]
9. Facial asymmetry in patients with hemifacial spasm before and after botulinum toxin A treatment.
Xiao L; Pan Y; Zhang X; Hu Y; Cai L; Nie Z; Pan L; Li B; He Y; Jin L
Neurol Sci; 2016 Nov; 37(11):1807-1813. PubMed ID: 27431279
[TBL] [Abstract][Full Text] [Related]
10. Pilot cohort study of endoscopic botulinum neurotoxin injection in Parkinson's disease.
Triadafilopoulos G; Gandhy R; Barlow C
Parkinsonism Relat Disord; 2017 Nov; 44():33-37. PubMed ID: 28847681
[TBL] [Abstract][Full Text] [Related]
11. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
12. Current and potential urological applications of botulinum toxin A.
Jiang YH; Liao CH; Kuo HC
Nat Rev Urol; 2015 Sep; 12(9):519-33. PubMed ID: 26260879
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of MR-Tractography Findings in Hemifacial Spasm Patients Injected with Botulinum Neurotoxin.
Cavus H; İşeri P; Öztürk O; Anık Y
Neurol India; 2022; 70(2):543-547. PubMed ID: 35532617
[TBL] [Abstract][Full Text] [Related]
14. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
Blumenfeld AM; Dodick DW; Silberstein SD
Dermatol Clin; 2004 Apr; 22(2):167-75. PubMed ID: 15222577
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin in pain treatment.
Colhado OC; Boeing M; Ortega LB
Rev Bras Anestesiol; 2009; 59(3):366-81. PubMed ID: 19488551
[TBL] [Abstract][Full Text] [Related]
16. Spasticity in practice (SPACE): an international non-interventional study of botulinum neurotoxin type A in treatment-naïve subjects with spasticity.
Harriss J; Roche N; Cantú-Brito C; Khatkova S; Säterö P; Heitmann S; Simon O; Kliebe-Frisch C; Comes G; Jost WH
Neurol Neurochir Pol; 2021; 55(2):165-173. PubMed ID: 33433902
[TBL] [Abstract][Full Text] [Related]
17. Therapy influences goal attainment following botulinum neurotoxin injection for focal spasticity in adults with neurological conditions.
Moore EJ; Olver J; Bryant AL; McKenzie DP; Williams G
Brain Inj; 2018; 32(7):948-956. PubMed ID: 29718712
[TBL] [Abstract][Full Text] [Related]
18. Botulinum Toxin in Secondarily Nonresponsive Patients with Spasmodic Dysphonia.
Mor N; Tang C; Blitzer A
Otolaryngol Head Neck Surg; 2016 Sep; 155(3):458-61. PubMed ID: 27143711
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin A (Botox) and sweating-dose efficacy and comparison to other BoNT preparations.
Schlereth T; Mouka I; Eisenbarth G; Winterholler M; Birklein F
Auton Neurosci; 2005 Feb; 117(2):120-6. PubMed ID: 15664565
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of botulinum toxin A for upper and lower limb spasticity in children with cerebral palsy: a summary of evidence.
Lukban MB; Rosales RL; Dressler D
J Neural Transm (Vienna); 2009 Mar; 116(3):319-31. PubMed ID: 19142573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
